Akebia Therapeutics Inc (AKBA) concluded trading on Wednesday at a closing price of $3.99, with 4.7 million shares of worth about $18.74 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 107.81% during that period and on July 09, 2025 the price saw a gain of about 7.55%. Currently the company’s common shares owned by public are about 261.64M shares, out of which, 251.62M shares are available for trading.
Stock saw a price change of 11.76% in past 5 days and over the past one month there was a price change of 0.50%. Year-to-date (YTD), AKBA shares are showing a performance of 326.42% which increased to 110.00% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.93 but also hit the highest price of $4.08 during that period. The average intraday trading volume for Akebia Therapeutics Inc shares is 5.04 million. The stock is currently trading 9.03% above its 20-day simple moving average (SMA20), while that difference is up 26.30% for SMA50 and it goes to 82.69% higher than SMA200.
Akebia Therapeutics Inc (NASDAQ: AKBA) currently have 261.64M outstanding shares and institutions hold larger chunk of about 36.60% of that.
The stock has a current market capitalization of $1.05B and its 3Y-monthly beta is at 0.97. It has posted earnings per share of -$0.22 in the same period. It has Quick Ratio of 2.02 while making debt-to-equity ratio of 8.39. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AKBA, volatility over the week remained 5.43% while standing at 5.78% over the month.
Stock’s fiscal year EPS is expected to rise by 80.61% while it is estimated to increase by 215.62% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on June 04, 2025 offering a Buy rating for the stock and assigned a target price of $8 to it. Coverage by Leerink Partners stated Akebia Therapeutics Inc (AKBA) stock as an Outperform in their note to investors on April 28, 2025, suggesting a price target of $7 for the stock. On April 01, 2025, Jefferies Initiated their recommendations, while on November 29, 2023, BTIG Research Resumed their ratings for the stock with a price target of $4. Stock get a Buy rating from H.C. Wainwright on August 28, 2023.
